Drospirenone (Slynd)

Abstract

CADTH recommends that Slynd should be reimbursed by public drug plans for conception control in adolescent and adult women if certain conditions are met. Slynd should be covered for conception control in adolescent and adult women provided that Slynd is listed in a similar way to other oral contraceptive pills currently reimbursed by public drug plans for the prevention of pregnancy. Slynd should only be reimbursed if the cost does not exceed that of other progestin-only pills (POPs) for contraception.